<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04162834</url>
  </required_header>
  <id_info>
    <org_study_id>20191111</org_study_id>
    <nct_id>NCT04162834</nct_id>
  </id_info>
  <brief_title>Effect of Papaverine on Renal Artery Blood Flow Volume</brief_title>
  <official_title>Effect of Papaverine on Intraoperative Renal Artery Blood Flow Volume in Patients Undergoing Robot-assisted Partial Nephrectomy : a Randomized, Double-blind, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of papaverine on renal artery blood flow
      after declamping of renal artery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the effect of papaverine on renal artery blood flow
      after declamping of renal artery in patients undergoing robot assisted partial nephrectomy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal artery blood flow</measure>
    <time_frame>at 2 minutes after papaverine administration</time_frame>
    <description>Renal artery blood flow 2 minutes after papaverine administration by doppler sonography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>estimated glomerular filtration rate</measure>
    <time_frame>at postoperative day 0</time_frame>
    <description>estimated glomerular filtration rate using KIDGO equation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estimated glomerular filtration rate</measure>
    <time_frame>at postoperative day 1</time_frame>
    <description>estimated glomerular filtration rate using KIDGO equation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estimated glomerular filtration rate</measure>
    <time_frame>at postoperative day 4</time_frame>
    <description>estimated glomerular filtration rate using KIDGO equation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estimated glomerular filtration rate</measure>
    <time_frame>at postoperative day 14</time_frame>
    <description>estimated glomerular filtration rate using KIDGO equation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estimated glomerular filtration rate</measure>
    <time_frame>at postoperative month 3</time_frame>
    <description>estimated glomerular filtration rate using KIDGO equation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glomerular filtration rate using renal scan</measure>
    <time_frame>at postoperative month 3</time_frame>
    <description>glomerular filtration rate using renal scan</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Kidney Cancer</condition>
  <arm_group>
    <arm_group_label>Papaverine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediately after the renal artery declamping, papaverine 30 mg (1 ample, 1 ml) is mixed with 5 ml of normal saline (total 6 ml) and sprinkled around the renal artery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immediately after the renal artery declamping, normal saline 6 ml is sprinkled around the renal artery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Papaverine</intervention_name>
    <description>Immediately after the renal artery declamping, papaverine 30 mg (1 ample, 1 ml) is mixed with 5 ml of normal saline (total 6 ml) and sprinkled around the renal artery.</description>
    <arm_group_label>Papaverine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Immediately after the renal artery declamping, normal saline 6 ml is sprinkled around the renal artery.</description>
    <arm_group_label>Normal saline group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with kidney cancer.

          -  Patients undergoing robot assisted partial nephrectomy under general anesthesia

          -  20 years old ≤ age &lt;80 years old

          -  Patients who voluntarily agreed to this clinical study

          -  eGFR ≥ 60 ml / min / 1.73 m2 (Chronic Kidney Disease Epidemiology Patients with
             Collaboration)

        Exclusion Criteria:

          -  The tumor ≥ 7 cm in size

          -  Multiple renal mass

          -  If the surgery plan is changed due to open

          -  When surgery is performed together with other surgery

          -  Multiple renal artery

          -  Patients with hypersensitivity to papaverine

          -  Patients with atrioventricular block

          -  Pregnant and lactating women

          -  Patients using levodopa

          -  Refusal of patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Kug Kim, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Young-Kug Kim, MD,PhD</last_name>
    <phone>82-2-3010-5976</phone>
    <email>kyk@amc.seoul.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jihion Yu, MD</last_name>
    <phone>82-2-3010-3868</phone>
    <email>yujihion@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Kug Kim, MD,PhD</last_name>
      <phone>82-2-3010-5976</phone>
      <email>kyk@amc.seoul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 10, 2019</study_first_submitted>
  <study_first_submitted_qc>November 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2019</study_first_posted>
  <last_update_submitted>January 12, 2020</last_update_submitted>
  <last_update_submitted_qc>January 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Young-Kug Kim</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papaverine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

